


Deslanoside

Cat. No.:	HY-A0154		
CAS No.:	17598-65-1		
Molecular Formula:	C ₄₇ H ₇₄ O ₁₉		
Molecular Weight:	943.08		
Target:	Na ⁺ /K ⁺ ATPase; Drug Metabolite		
Pathway:	Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (106.04 mM; Need ultrasonic)				
		Solvent Concentration	Mass		
	Preparing Stock Solutions	1 mM	1 mg	5 mg	10 mg
		5 mM	0.2121 mL	1.0604 mL	2.1207 mL
10 mM		0.1060 mL	0.5302 mL	1.0604 mL	
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	<ol style="list-style-type: none"> Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (2.21 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (2.21 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (2.21 mM); Clear solution 				

BIOLOGICAL ACTIVITY

Description	Deslanoside (Desacetyllanatoside C) is a rapidly acting cardiac glycoside used to treat congestive heart failure and supraventricular arrhythmias due to reentry mechanisms, and to control ventricular rate in the treatment of chronic atrial fibrillation. Deslanoside inhibits the Na-K-ATPase membrane pump, resulting in an increase in intracellular sodium and calcium concentrations ^{[1][2][3]} .
In Vitro	Deslanoside (Desacetyllanatoside C) is a metabolite of Lanatoside C ^[4] . Deslanoside increases forearm blood flow and cardiac index and decreased heart rate concomitant with a marked decrease in skeletal muscle sympathetic nerve activity

measured as an indicator of centrally mediated sympathetic nervous system activity^[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Klys M, et al. Determination of deslanoside in antemortem and postmortem specimens. Unusual case report. *Forensic Sci Int.* 1990 Apr;45(3):231-8.
- [2]. Hauptman PJ, et al. Digitalis. *Circulation.* 1999 Mar 9;99(9):1265-70.
- [3]. Wang L, et al. Ontology-based systematical representation and drug class effect analysis of package insert-reported adverse events associated with cardiovascular drugs used in China. *Sci Rep.* 2017 Oct 23;7(1):13819.
- [4]. Deslanoside.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA